GE HealthCare Technologies Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
GE HealthCare is a global medical technology, pharmaceutical diagnostics, and digital solutions company operating through Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The filing covers the three and six months ended June 30, 2023, compared primarily with the corresponding 2022 periods. GE completed the spin-off of GE HealthCare on January 3, 2023; therefore, 2022 results are historical carve-out results and may not represent the costs or performance of the stand-alone company.
Key financial metrics
| Metric | Q2 2023 | Q2 2022 | Change |
|---|---|---|---|
| Total revenue | $4.817 billion | $4.484 billion | +7%; +9% organically |
| Gross profit | $1.940 billion | $1.796 billion | +8% |
| Operating income | $570 million | $631 million | -10% |
| Operating margin | 11.8% | 14.1% | -230 basis points |
| Net income attributable to GE HealthCare | $418 million | $485 million | -14% |
| Net margin | 8.7% | 10.8% | -210 basis points |
| Diluted EPS from continuing operations | $0.91 | $1.04 | -$0.13 |
| Adjusted EBIT | $711 million | $719 million | -1% |
| Adjusted EBIT margin | 14.8% | 16.0% | -120 basis points |
For the six months ended June 30, 2023, revenue was $9.524 billion, up 8% reported and 11% organically. Operating income was $1.129 billion, down 1%, and net income attributable to GE HealthCare was $790 million, down 10%. Adjusted EBIT was $1.375 billion, up 4%, while adjusted net income was $807 million, down 16%.
- Q2 segment revenue growth was 7% in Imaging, 1% in Ultrasound, 8% in PCS, and 19% in PDx. PDx and PCS delivered segment EBIT growth, while Imaging and Ultrasound EBIT declined.
- Six-month segment revenue growth was 7% in Imaging, 3% in Ultrasound, 9% in PCS, and 17% in PDx.
- Cash from operating activities was $401 million for the six months, compared with $449 million in 2022. Free cash flow was $189 million, down from $293 million.
- Capital expenditures were $213 million, compared with $159 million in the prior-year period. Investing cash outflows included $147 million for acquisitions, primarily Caption Health.
- Cash, cash equivalents, and restricted cash totaled $1.939 billion at June 30, 2023, compared with $1.445 billion at December 31, 2022.
- Total debt was approximately $10.238 billion at June 30, 2023, compared with $8.250 billion at year-end 2022. The increase primarily reflects the $2.0 billion term-loan draw in connection with the spin-off. The weighted-average interest rate was 5.98%.
- The company had $3.5 billion of revolving credit capacity with no outstanding borrowings under those revolving facilities and was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Revenue increased primarily because of higher product sales, pricing, improved supply-chain fulfillment, new product introductions, and stronger demand in PDx. Foreign-exchange effects reduced reported growth.
- Operating profitability declined despite revenue growth. SG&A increased $164 million in Q2, and research and development increased $41 million, reflecting stand-alone company costs, commercial investments, and planned R&D investment.
- Interest and other financial charges increased to $137 million from $12 million in Q2 and to $273 million from $16 million for the six-month period, primarily because of the company’s debt issued in November 2022 and the January 2023 term-loan draw.
- Non-operating benefit income increased substantially because pension and other postretirement plans were transferred from GE in connection with the spin-off, partially offsetting higher interest expense.
- Q2 included $72 million of spin-off and separation costs; six-month costs totaled $130 million. Restructuring expense was $19 million in Q2 and $31 million year to date, with approximately $35 million of additional restructuring expense expected, primarily in 2023.
- GE HealthCare acquired Caption Health for $127 million upfront, with a $10 million future holdback and potential earn-out payments valued at $13 million. The acquisition added preliminary goodwill of $94 million and intangible assets of $60 million.
Guidance, outlook, commentary, and risks
The filing text does not provide a clear formal full-year financial guidance range. Management stated that existing cash, expected operating cash flow, capital-market access, and credit facilities should be sufficient for operations, taxes, debt service, and business investment for at least the next 12 months.
- Management cited continued opportunities from product innovation, pricing, supply-chain improvement, and demand across the portfolio, while noting cost inflation and planned investments.
- Russia and Ukraine-related revenues were $155 million for the first six months. Expanded export licensing requirements affected the company’s ability to supply Russian customers in Q2, and further disruption or failure to obtain licenses remains possible.
- Key risks include competition, reimbursement changes, supply-chain disruption, inflation, foreign-exchange and interest-rate volatility, cybersecurity and data-security incidents, product liability, regulatory compliance, litigation, and the company’s ability to operate effectively as a newly independent public company.
- The company faces pension and postretirement obligations. Total postretirement plan funded status was a deficit of approximately $4.323 billion, and 2023 benefit payments were expected to total approximately $353 million.
- Remaining performance obligations were $14.309 billion at June 30, 2023, substantially unchanged from year-end. Product obligations were $4.992 billion and services obligations were $9.317 billion.
- The company reported a pending Anti-Terrorism Act lawsuit relating to contracts with the Iraqi Ministry of Health. The filing states that a meaningful estimate of potential loss was not available.
- GE HealthCare had approximately $693 million of unused letters of credit, bank guarantees, bid bonds, and surety bonds, plus approximately $44 million of other guarantees. Its maximum exposure on remaining performance guarantees issued on behalf of GE was approximately $114 million, subject to GE reimbursement.
Important facts for investors to verify
- Reconcile reported revenue growth with organic growth and assess the sustainability of pricing and supply-chain benefits.
- Monitor whether SG&A, R&D, spin-off costs, and restructuring charges normalize as the stand-alone operating model matures.
- Evaluate debt-servicing capacity, refinancing needs beginning with the $1.0 billion of senior notes due in November 2024, interest-rate exposure, and covenant compliance.
- Track conversion of the $14.309 billion remaining performance obligation balance into revenue and cash flow.
- Assess free-cash-flow recovery given lower operating cash flow, higher capital expenditures, pension funding, and acquisition spending.
- Review pension and postretirement funding requirements, tax audits, tax indemnities with GE, litigation exposure, export-license developments in Russia, and other guarantees and contingencies.
- Consider comparability limitations because 2022 results were prepared as GE carve-out financial statements and included allocations that may differ from stand-alone costs.